BeiGene News | StatMuse Money

Yahoo Finance • 17 days ago

ONC Crosses Above Average Analyst Target

In recent trading, shares of BeOne Medicines Ltd (Symbol: ONC) have crossed above the average analyst 12-month target price of $345.89, changing hands for $346.45/share. When a stock reaches the target an analyst has set, the analyst logi... Full story

Mentioned:

CMG

Yahoo Finance • 28 days ago

BeOne Medicines succeeds in Phase 1/2 study for lymphoma therapy

[Lymphoma blood test] BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) announced Friday that sonrotoclax, its experimental therapy targeting a hematological cancer called mantle cell lymphoma, succeeded as a late-line op... Full story

Yahoo Finance • last month

Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M

BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) is selling its royalty rights on the worldwide sales, excluding China, of Amgen’s (NASDAQ:AMGN [https://seekingalpha.com/symbol/AMGN]) cancer drug Imdelltra (tarlatamab-dll... Full story

Mentioned:

AMGN
RPRX

Yahoo Finance • last month

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story

Mentioned:

AMD
ARQT
MEDP
NVDA
TARS

Yahoo Finance • last month

Oncolytics Biotech announces voting results from annual meeting

SAN DIEGO - Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), whose stock has delivered an impressive 56% return year-to-date according to InvestingPro data, reported Monday that shareholders elected all eight director nominees at its Annua... Full story

Mentioned:

ONCY
T

Yahoo Finance • 2 months ago

Baillie Gifford's Strategic Moves: Shopify Inc. Sees a Significant Reduction

Exploring the Latest 13F Filing and Investment Adjustments Baillie Gifford (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into its investment moves during this period. Established... Full story

Mentioned:

AMZN
APP
DG
ESTC
FTAI
MELI
NVDA

Yahoo Finance • 2 months ago

BeOne Medicines outlines $5B–$5.3B 2025 revenue target as BRUKINSA leads BTK market and global expansion accelerates

Earnings Call Insights: BeOne Medicines Ltd. (ONC) Q2 2025 MANAGEMENT VIEW * John V. Oyler, CEO, reported "Our revenue reached $1.3 billion, which represents 42% year-on-year growth. GAAP earnings per ADS grew $2 from Q2 of last year,... Full story

Mentioned:

OR
V

Yahoo Finance • 2 months ago

Onc stock hits 52-week high at 309.25 USD

Onc stock reached a significant milestone, hitting a 52-week high of 309.25 USD. The $36.11 billion market cap company’s achievement reflects a robust performance over the past year, during which BeOne Medicines AG DRC, the company behind... Full story

Mentioned:

ONCY
T

Yahoo Finance • 2 months ago

3 Stocks Estimated To Be Trading At A Discount Of Up To 49.9%

Over the last 7 days, the United States market has remained flat, yet it has experienced a notable increase of 17% over the past year with earnings forecasted to grow by 15% annually. In this environment, identifying stocks that are tradin... Full story

Yahoo Finance • 3 months ago

Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports

(Reuters) -AstraZeneca is in talks with Summit Therapeutics (NASDAQ:SMMT) to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with the matter.... Full story

Mentioned:

AZN
SMMT

Yahoo Finance • 3 months ago

BeOne Medicines price target raised to $330 from $313 at Morgan Stanley

Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $330 from $313 and keeps an Overweight rating on the shares following the R&D day that highlighted the company’s pipeline programs. Management is targeting a 2026 ap... Full story

Yahoo Finance • 3 months ago

Palantir, Nike lead Friday's market cap stock movers

Friday’s trading session is showcasing significant movements among several stocks, particularly within the mega-cap and large-cap categories. Stocks like Palantir Technologies Inc (NASDAQ:PLTR) and General Electric (NYSE:GE) are experi... Full story

Mentioned:

Yahoo Finance • 3 months ago

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

BRUKINSA, sonrotoclax, and BTK CDAC data, including combinations, are designed to comprehensively address unmet needs across CLL patient populations Promising new data from pipeline assets in breast, lung, and GI cancer franchises, includ... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics' SWOT analysis: promising BTK degrader stock faces challenges

Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company focused on developing novel therapies for cancer and immune disorders, has been garnering attention from investors and analysts alike. According to InvestingPro data, the... Full story

Mentioned:

GILD
NRIX
PFE
SNY

Yahoo Finance • 3 months ago

BeOne gets FDA nod for tablet version of zanubrutinib

[Female pharmacist holding medicines] izusek/E+ via Getty Images BeOne Medicines (NASDAQ:ONC [https://seekingalpha.com/symbol/ONC]) said on Wednesday that it has received approval from the U.S. FDA for a new tablet version of its medicati... Full story